Medical technology company Teleflex has announced the commercial availability of its UroLift 2 System and UroLift ATC System in the US.
According to Teleflex, the UroLift 2 System has enhanced workflow, with a single ergonomic trigger and a better suture cutter in a smaller device and packaging footprint.
It is a minimally invasive treatment for symptoms of benign prostatic hyperplasia in the lower urinary system (BPH) in men aged 45 years and older who have symptoms of an enlarged prostate with a volume of up to 100 cc.
The UroLift permanent implants treat prostate blockage without heating, cutting, destroying, or removing prostate tissue during outpatient surgery.
The UroLift ATC System gives doctors an improved delivery tip especially developed to treat patients with obstructed median lobes.
Teleflex president and chief executive officer Liam Kelly said: “We are proud to share the new developments and product enhancements of the UroLift System with the urology community at AUA.
“The enhanced UroLift ATC System will enable urologists to treat more patients with a broad range of anatomies, including those with obstructive middle lobes, while the enhanced features of the UroLift 2 System can help improve workflow.”
Summit Urology Group MD, FACS, Steven Gange said: “I have had occasion to use the UroLift ATC Advanced Tissue Control System multiple times and my experience has been very positive.
“The advanced engineering features of the UroLift ATC System make it easier to secure and retract prostate tissue which is especially useful when treating patients with large obstructive middle lobes.”
The medical technology firm will update the urology community through presentations at the 2022 American Urological Association (AUA) annual meeting from 13-16 May in New Orleans.
Teleflex will present the discussion on the need for minimally invasive BPH treatments as well as information on the UroLift 2 System.
